Sentences with phrase «neoplasm in»

Emma Young dates the oldest known tumour in the human ancestral line — a fibrous dysplastic neoplasm in a Neanderthal...

Ellagic acid reduced the number of altered foci and the incidence of hepatocellular neoplasms in rats with liver cancer induced by N -2-fluorenylacetamide (Tanaka).

Description — Multiple myeloma accounts for less than 1 % of all neoplasms in animals, but among hematopoietic, primary and secondary tumors it consists of 8 % and 3.6 % respectively.

Skin tumors are the most commonly diagnosed neoplasms in veterinary medicine.2 These neoplasms represent a diverse group of benign and malignant growths arising from a variety of cell types.

Not exact matches

«Prudential's methodical actuary,» as I wrote in Truth, «had gone through his company's own life insurance payouts for the previous year and had discovered that two words kept recurring in the ledgers: malignant neoplasm.»

Once triggered, the «subroutine» of cancer results in a neoplasm (a group of new, cancerous cells) becoming mobile; this is metastasis, responsible for most deaths from cancer.

From a u-CT scan and an X-ray, researchers identified a fibrous dysplastic neoplasm — today, the most common form of benign bone tumor in humans — located on a Neandertal left rib fragment that measured 30 mm (4 1/2 inches) long.

The two main causes of death for the cyclists were neoplasms (32.2 %), and cardiovascular diseases (29 %), both occurring less frequently than in the general public (SMRs of 0.56 and 0.67 respectively).

Using a fluorescent protein to detect Rgs16 expression, the investigators found that this gene is induced by pancreatic tumor formation starting from its earliest manifestation as ductal neoplasm all the way to advanced solid tumor in a spatially and temporally coincidental manner.

He has extensive experience treating patients with blood cancers and holds a particular interest in chronic myeloid leukemia and myeloproliferative neoplasms, a group of blood cancers related to leukemia.

The lesions evaluated in this study that can become cancerous are known as intraductal papillary mucinous neoplasms.

These studies revealed that the void's physical characteristics — the type and location of missing bone — were consistent with a fibrous dysplastic neoplasm, a tumor caused by a bone growth disorder, the scientists report online today in PLOS ONE.

According to a new «proof of principle» study published in Aug. 27 issue of Cancer Prevention Research, Moffitt Cancer Center researchers hope to improve pancreatic cancer survival rates by identifying markers in the blood that can pinpoint patients with premalignant pancreatic lesions called intraductal papillary mucinous neoplasms (IPMNs).

Myeloproliferative neoplasms (MPN) are diagnosed in around 3,300 UK patients every year and cause an overproduction of blood cells creating a significant impact on quality - of - life, with symptoms such as night sweats, itching and tiredness.

Phase I Study of MK - 3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed / Refractory or Disseminated Malignant Neoplasm

Mice have a high incidence of Hodgkin's - like reticulum cell neoplasm at 18 months of age and pituitary tumors in old multiparous females.

«Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123 - Specific CAR T Cells: A First - in - Human Clinical Trial» is presented at the ASH Annual Meeting Dec. 9 to 12, 2017.

BAFF Levels Are Elevated in Paediatric Patients With Acute Lymphoblastic Leukaemia Compared to Other B - Lineage Neoplasms

Abstract Neuroblastoma is an embryonal neoplasm arising from the peripheral nervous system that accounts for 15 % of cancer deaths in childhood.

We screened the coding sequences of 518 protein kinases (approximately 1.3 Mb of DNA per sample) for somatic mutations in 26 primary lung neoplasms and seven lung cancer cell lines.

In this type of plasma cell neoplasm, less than 10 % of the bone marrow is made up of abnormal plasma cells and there is no cancer.

Plasma cell neoplasms are diseases in which abnormal plasma cells or myeloma cells form tumors in the bones or soft tissues of the body.

Panobinostat is an HDAC inhibitor used in the treatment of multiple myeloma and other plasma cell neoplasms.

Plasma cell neoplasms are most common in people who are middle aged or older.

Daratumumab and elotuzumab are monoclonal antibodies used in the treatment of multiple myeloma and other plasma cell neoplasms.

Bortezomib, carfilzomib, and ixazomib are proteasome inhibitors used in the treatment of multiple myeloma and other plasma cell neoplasms.

She is a founding member of the National Comprehensive Cancer Network (NCCN) Myeoproliferative Neoplasms Panel which is charged with making recommendations for best practice in the diagnosis, treatment and management for MPNs.

Senderowicz AM, Headlee D, Stinson SF, et al: Phase I trial of continuous infusion flavopiridol, a novel cyclin - dependent kinase inhibitor, in patients with refractory neoplasms.

DATE: April 3 TIME: 3:20 p.m. LOCATION: Room 204, Level 2, Washington Convention Center TITLE: Germline mutations in cancer predisposition genes and risk for subsequent neoplasms among long - term survivors of childhood cancer in the St. Jude Lifetime Cohort ABSTRACT: 3001

Dr. Tan specializes in management of tumors of the: - Pancreas (including cysts & chronic pancreatitis)- Liver (primary & metastatic)- Stomach - Duodenum and small intestine (including carcinoid tumors)- Bile duct and gallbladder - Retroperitoneum (including sarcomas) Dr. Tan performs clinical and translational research in pancreatic neoplasms and metastatic colorectal cancer.

Dr. Tan performs clinical and translational research in pancreatic neoplasms and metastatic colorectal cancer.

In 2005, the identification of an activating mutation in JAK2 (the V617F mutation) as a STAT5 - activating and disease - causing genetic alteration in a significant proportion of patients with myeloproliferative neoplasms (MPNs) has emphasized the oncogenic role of the JAK tyrosine kinases in hematologic malignancies.2 — 5 JAK2 is a member of the Janus tyrosine kinase family comprising three other mammalian non-receptor tyrosine kinases (JAK1, JAK3 and TYK2) that associate with cytokine receptors lacking intrinsic kinase activity to mediate cytokine - induced signal transduction and activation of STAT transcription factors.6 All JAKs share a similar protein structure and contain a tyrosine kinase domain at the C - terminus flanked by a catalytically inactive pseudokinase domain with kinase - regulatory activity, by an atypical SH2 domain and by a FERM domain that mediates association to the membrane - proximal region of the cytokine receptors.7, 8 Soon after the discovery of JAK2 V617F, we and others described that activating JAK1 mutations are relatively common in adult patients with T - cell acute lymphoblastic leukemia (ALL) and participate in ALL development allowing for constitutive activation of STAT5.9 — 11 Several STAT5 - activating JAK1 mutations were also reported in AML and breast cancer patients.In 2005, the identification of an activating mutation in JAK2 (the V617F mutation) as a STAT5 - activating and disease - causing genetic alteration in a significant proportion of patients with myeloproliferative neoplasms (MPNs) has emphasized the oncogenic role of the JAK tyrosine kinases in hematologic malignancies.2 — 5 JAK2 is a member of the Janus tyrosine kinase family comprising three other mammalian non-receptor tyrosine kinases (JAK1, JAK3 and TYK2) that associate with cytokine receptors lacking intrinsic kinase activity to mediate cytokine - induced signal transduction and activation of STAT transcription factors.6 All JAKs share a similar protein structure and contain a tyrosine kinase domain at the C - terminus flanked by a catalytically inactive pseudokinase domain with kinase - regulatory activity, by an atypical SH2 domain and by a FERM domain that mediates association to the membrane - proximal region of the cytokine receptors.7, 8 Soon after the discovery of JAK2 V617F, we and others described that activating JAK1 mutations are relatively common in adult patients with T - cell acute lymphoblastic leukemia (ALL) and participate in ALL development allowing for constitutive activation of STAT5.9 — 11 Several STAT5 - activating JAK1 mutations were also reported in AML and breast cancer patients.in JAK2 (the V617F mutation) as a STAT5 - activating and disease - causing genetic alteration in a significant proportion of patients with myeloproliferative neoplasms (MPNs) has emphasized the oncogenic role of the JAK tyrosine kinases in hematologic malignancies.2 — 5 JAK2 is a member of the Janus tyrosine kinase family comprising three other mammalian non-receptor tyrosine kinases (JAK1, JAK3 and TYK2) that associate with cytokine receptors lacking intrinsic kinase activity to mediate cytokine - induced signal transduction and activation of STAT transcription factors.6 All JAKs share a similar protein structure and contain a tyrosine kinase domain at the C - terminus flanked by a catalytically inactive pseudokinase domain with kinase - regulatory activity, by an atypical SH2 domain and by a FERM domain that mediates association to the membrane - proximal region of the cytokine receptors.7, 8 Soon after the discovery of JAK2 V617F, we and others described that activating JAK1 mutations are relatively common in adult patients with T - cell acute lymphoblastic leukemia (ALL) and participate in ALL development allowing for constitutive activation of STAT5.9 — 11 Several STAT5 - activating JAK1 mutations were also reported in AML and breast cancer patients.in a significant proportion of patients with myeloproliferative neoplasms (MPNs) has emphasized the oncogenic role of the JAK tyrosine kinases in hematologic malignancies.2 — 5 JAK2 is a member of the Janus tyrosine kinase family comprising three other mammalian non-receptor tyrosine kinases (JAK1, JAK3 and TYK2) that associate with cytokine receptors lacking intrinsic kinase activity to mediate cytokine - induced signal transduction and activation of STAT transcription factors.6 All JAKs share a similar protein structure and contain a tyrosine kinase domain at the C - terminus flanked by a catalytically inactive pseudokinase domain with kinase - regulatory activity, by an atypical SH2 domain and by a FERM domain that mediates association to the membrane - proximal region of the cytokine receptors.7, 8 Soon after the discovery of JAK2 V617F, we and others described that activating JAK1 mutations are relatively common in adult patients with T - cell acute lymphoblastic leukemia (ALL) and participate in ALL development allowing for constitutive activation of STAT5.9 — 11 Several STAT5 - activating JAK1 mutations were also reported in AML and breast cancer patients.in hematologic malignancies.2 — 5 JAK2 is a member of the Janus tyrosine kinase family comprising three other mammalian non-receptor tyrosine kinases (JAK1, JAK3 and TYK2) that associate with cytokine receptors lacking intrinsic kinase activity to mediate cytokine - induced signal transduction and activation of STAT transcription factors.6 All JAKs share a similar protein structure and contain a tyrosine kinase domain at the C - terminus flanked by a catalytically inactive pseudokinase domain with kinase - regulatory activity, by an atypical SH2 domain and by a FERM domain that mediates association to the membrane - proximal region of the cytokine receptors.7, 8 Soon after the discovery of JAK2 V617F, we and others described that activating JAK1 mutations are relatively common in adult patients with T - cell acute lymphoblastic leukemia (ALL) and participate in ALL development allowing for constitutive activation of STAT5.9 — 11 Several STAT5 - activating JAK1 mutations were also reported in AML and breast cancer patients.in adult patients with T - cell acute lymphoblastic leukemia (ALL) and participate in ALL development allowing for constitutive activation of STAT5.9 — 11 Several STAT5 - activating JAK1 mutations were also reported in AML and breast cancer patients.in ALL development allowing for constitutive activation of STAT5.9 — 11 Several STAT5 - activating JAK1 mutations were also reported in AML and breast cancer patients.in AML and breast cancer patients.10

Solid pseudopapillary neoplasms are slow - growing pancreatic tumors that are usually cancerous, occurring most often in young, African - American women.

Myeloproliferative neoplasms (MPNs) are blood disorders in which the bone marrow makes too many of one or more types of blood cells — white blood cells, red blood cells or platelets.

Due to the inhibition of RNA transcription, ActD has been found to have antineoplastic properties in the treatment of various malignant neoplasms including Wilm's tumour [14].

The more recent identification of mutations in calreticulin brought with it a sense of completeness, with most patients with myeloproliferative neoplasm now having a biological basis for their excessive myeloproliferation.

In living humans effects of the neoplasm present a broad spectrum of symptoms, from asymptomatic to debilitating.

Multiple myeloma and other plasma cell neoplasms (cancers) are diseases in which the body makes too many plasma cells.

Myeloproliferative neoplasms are a group of rare disorders of the bone marrow that cause an increase in the number of blood cells.

Substantial progress has been made in our understanding of the pathogenetic basis of myeloproliferative neoplasms.

In addition to confirming an overall survival advantage and reduction in cardiovascular - related deaths among persons who participate in regular exercise, we also found a reduced rate of deaths from other causes including malignant neoplasms and neurologic disorderIn addition to confirming an overall survival advantage and reduction in cardiovascular - related deaths among persons who participate in regular exercise, we also found a reduced rate of deaths from other causes including malignant neoplasms and neurologic disorderin cardiovascular - related deaths among persons who participate in regular exercise, we also found a reduced rate of deaths from other causes including malignant neoplasms and neurologic disorderin regular exercise, we also found a reduced rate of deaths from other causes including malignant neoplasms and neurologic disorders.

Ten percent of all feline neoplasms occur in the mouth and of these almost 90 % are malignant.

Another is when they begin to grow abnormally, resulting in benign (not cancer) or cancerous tumors (also called neoplasms).

A thorough physical and orthopedic examination should be performed in all dog diagnosed with a suspected musculoskeletal neoplasm to evaluate for evidence of metastatic disease and plan the most appropriate treatment.Read More»

Bladder Cancer in Dogs - this type of cancer refers to a tumor or neoplasm that forms in the urinary tract.

Bone Bone neoplasms are seen most often in large - breed dogs or dogs older than 7 years; they are rarely seen in cats.

In dogs, 50 % of all breast neoplasms are malignant, whereas in cats, more than 85 % of breast neoplasms are malignanIn dogs, 50 % of all breast neoplasms are malignant, whereas in cats, more than 85 % of breast neoplasms are malignanin cats, more than 85 % of breast neoplasms are malignant.

In some cases, taking a tissue sample (biopsy) from the neoplasm for microscopic examination may also be necessary.

There is also controversy as to what criteria should be used to establish whether a lesion that arises in the skin or soft tissues is or is not a neoplasm, and if so, whether it is benign or malignant.»

Malignant or cancerous tumors can originate in the eye or spread from neoplasms (growths) in other areas of the body.